
Rekovelle Market Report 2026
Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Rekovelle Market Overview
• The Rekovelle market growth in the historic period has been driven by increasing infertility rates, expansion of assisted reproductive technology clinics • Market expansion is supported by increasing demand for IVF procedures, growing preference for personalized fertility care • Growth Driver: Rising Infertility Rates Drive Market Growth In IVF Treatments • Market Trend: Profile Study Confirms As A Safe And Effective Personalized IVF Treatment • Europe was the largest region in 2025 and Asia-Pacific is the fastest growing region.What Is Covered Under Rekovelle Market?
Rekovelle is a fertility medication containing the recombinant hormone follitropin delta, used to stimulate ovarian follicle development in women undergoing in vitro fertilization (IVF). It helps produce multiple eggs, increasing the likelihood of successful fertilization and pregnancy. The main types of indications in rekovelle are controlled ovarian stimulation and polycystic ovary syndrome. Controlled ovarian stimulation (COS) is a fertility treatment where hormones are used to stimulate the ovaries to produce multiple eggs for fertilization, typically in in vitro fertilization (IVF). It is distributed through various channels such as hospitals, clinics, and pharmacies, catering to various end users such as pediatric, adult, and geriatric.
What Is The Rekovelle Market Size and Share 2026?
The growth in the historic period can be attributed to increasing infertility rates, expansion of assisted reproductive technology clinics, rising maternal age trends, improved availability of fertility medications, clinical validation of recombinant hormone therapies.What Is The Rekovelle Market Growth Forecast?
The growth in the forecast period can be attributed to increasing demand for IVF procedures, growing preference for personalized fertility care, expansion of fertility tourism, rising investment in reproductive health services, continued innovation in hormonal stimulation therapies. Major trends in the forecast period include increasing adoption of personalized fertility treatments, rising use of recombinant gonadotropins, growing focus on individualized ovarian stimulation protocols, expansion of ivf treatment volumes, enhanced precision in hormonal dosing.Global Rekovelle Market Segmentation
1) By Indication: Controlled Ovarian Stimulation, Polycystic Ovary Syndrome 2) By Distribution Channel: Hospitals, Clinics, Pharmacies 3) By End User: Pediatric, Adult, GeriatricWhat Are The Drivers Of The Rekovelle Market?
The increasing prevalence of infertility rates is expected to lead to growth of the rekovelle market going forward. Infertility rates refer to the proportion of couples or individuals within a specific population who are unable to conceive after trying for a certain period, typically one year, despite having regular, unprotected sexual intercourse. The increasing prevalence of infertility is driven by factors such as delayed childbearing, lifestyle changes, environmental toxins, and medical conditions, leading to a growing demand for fertility treatments. Rekovelle helps reduce infertility rates by improving ovarian response and enhancing the success of assisted reproductive technologies like IVF, increasing the chances of successful fertilization and pregnancy. For instance, in April 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 17.5% of the global adult population, or about 1 in 6 individuals, face infertility. Therefore, the increasing prevalence of infertility is due to the growth of the rekovelle industry. The increasing prevalence of genetic conditions is expected to propel the growth of the Rekovelle market going forward. Genetic conditions are disorders caused by abnormalities in an individual’s DNA, including mutations, deletions, or duplications. Genetic conditions are increasing due to advanced parental age, which raises the risk of DNA mutations in eggs and sperm. Rekovelle supports patients with genetically related fertility challenges by stimulating ovarian follicle development for effective IVF treatment. For instance, in March 2024, according to the Gene People, a UK-based registered charity, genetic conditions affect an estimated 1 in 25 children, impacting over 2.4 million children and adults in the UK. Therefore, the increasing prevalence of genetic conditions is driving the growth of the Rekovelle industry.Key Players In The Global Rekovelle Market
Major companies operating in the rekovelle market are Ferring Pharmaceuticals A/SGlobal Rekovelle Market Trends and Insights
Major companies operating in the Rekovelle market are focusing on developing innovative solutions, such as personalized ovarian stimulation, to meet the rising demand for more effective and safer fertility treatments. Personalized ovarian stimulation involves tailoring the therapy (drug dosage) to each individual’s characteristics, such as body weight and anti Müllerian hormone levels, rather than using a standard dose for everyone. In March 2023, Ferring Pharmaceuticals A/S, a Switzerland based pharmaceutical company, presented data from the PROFILE study, the first prospective, real world study of Rekovelle (follitropin delta). The results showed that about 74% of participants retrieved between 4 and 19 oocytes, and the ongoing pregnancy rates corresponded with those observed in previous Phase 3 trials. An individualized dosing algorithm (based on body weight and AMH) was used in 95% of the cases. These findings support Rekovelle’s efficacy and safety in a real world, personalized ovarian stimulation context.Regional Insights
Europe was the largest region in the rekovelle market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.What Defines the Rekovelle Market?
The rekovelle market consists of sales of products including injections, pre-filled syringes, vials, and dose adjuster kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Rekovelle Market Report 2026?
The rekovelle market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rekovelle industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Rekovelle Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $ billion |
| Revenue Forecast In 2035 | $ billion |
| Growth Rate | No CAGR found from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Indication, Distribution Channel, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Ferring Pharmaceuticals A/S |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
